论文部分内容阅读
大规模的高血压临床试验和心血管分子生物学研究表明,原发性高血压的发生发展伴随着许多细胞因子和生长因子的作用。脂联素(APN)是1995年首先由Schere等[1]从鼠的脂肪细胞分离出来,在动物和人类的试验中已经证实APN具有增加脂肪酸氧化,提高葡萄糖摄取量,改善胰岛素抵抗等作用。
Large-scale clinical trials of hypertension and cardiovascular molecular biology studies have shown that the occurrence and development of essential hypertension accompanied by many cytokines and growth factors. Adiponectin (APN) was first isolated from rat adipocytes by Schere et al. [1] in 1995. APN has been shown to increase fatty acid oxidation, increase glucose uptake, and improve insulin resistance in animal and human trials.